Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib in Recurrent Anaplastic Oligodendroglioma
NCT02530320Phase 2Completed
- Sponsor
- Grupo Español de Investigación en Neurooncología
- Start
- Oct 2015
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of palbociclib in Oligodendroglioma (OG) and oligoastrocytoma, sponsored by Grupo Español de Investigación en Neurooncología. Primary endpoint: Progression-free Survival at Six Months at 6 months. Started Oct 2015; status: completed.
02
Drugs
palbociclib
03
Conditions
Oligodendroglioma (OG)oligoastrocytoma
Beyond the preview
Go deeper on NCT02530320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02530320.